Imatinib Stada (Imatinib)

Imatinib is a tyrosine kinase inhibitor used in hematologic and solid‑tumor malignancies that involve BCR‑ABL, c‑KIT or PDGFR signaling.

• Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and achieves durable hematologic and cytogenetic responses.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): improves remission rates by targeting BCR‑ABL driven blasts.
• Gastrointestinal stromal tumor (GIST): inhibits c‑KIT driven tumor growth, leading to disease control and symptom relief.

• Imatinib selectively inhibits the intracellular tyrosine kinases BCR‑ABL, c‑KIT and platelet‑derived growth factor receptor (PDGFR). By binding to the ATP‑binding site of these enzymes, it blocks phosphorylation cascades that drive uncontrolled cell division and survival in malignant cells, thereby suppressing tumor growth and inducing apoptosis. The inhibition is sustained at therapeutic concentrations, leading to prolonged blockade of downstream signaling pathways such as MAPK and PI3K/AKT, which are essential for tumor cell proliferation and angiogenesis.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools, often transient.
• Fatigue: generalized tiredness.
• Edema: peripheral swelling, especially of ankles.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or hepatitis.
• Myelosuppression: neutropenia, anemia, or thrombocytopenia.
• Cardiotoxicity: left ventricular dysfunction or heart failure.

When prescribing Imatinib, clinicians should consider several safety precautions to minimize risk.

• Baseline assessment: obtain complete blood count, liver function tests and renal function before initiating therapy.
• Hepatic monitoring: repeat liver enzymes regularly as hepatotoxicity can develop during treatment.
• Hematologic monitoring: monitor CBC weekly initially to detect neutropenia or anemia.
• Cardiac evaluation: assess cardiac function in patients with pre‑existing heart disease.
• Drug interactions: review concomitant medications for CYP3A4 inhibitors or inducers.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise imatinib levels and risk toxicity.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower imatinib exposure and reduce efficacy.
• Antacids containing aluminum or magnesium: can reduce absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Proton pump inhibitors: may modestly decrease imatinib absorption; separate dosing by at least 2 hours.
• Warfarin: imatinib may enhance anticoagulant effect; monitor INR closely.
• Digoxin: possible increase in serum levels; observe for signs of toxicity.